혈관부종 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global angioedema treatment market size is expected to reach USD 3.92 Billion in 2034 from USD 1.63 Billion in 2025, growing at a CAGR of 10.23% during 2026-2034.This market is gaining importance as healthcare professionals seek effective approaches to managing angioedema, a condition characterized by swelling beneath the skin or in mucosal tissues. Angioedema may be associated with allergic reactions, certain medications, or hereditary conditions involving abnormalities in inflammatory pathways. Growing awareness of the condition, improved diagnostic capabilities, and increasing recognition of hereditary angioedema are supporting demand for appropriate treatments. Because some episodes can involve the airway and become life-threatening, timely recognition and access to suitable medical care remain essential. These factors are encouraging continued attention to treatment availability and disease management.

Market growth is supported by advances in targeted therapies, improved understanding of disease mechanisms, and increasing availability of specialized treatment options. Treatments vary according to the underlying cause and may include emergency medications for allergic reactions, therapies targeting bradykinin pathways in hereditary angioedema, and preventive treatments for eligible patients. Pharmaceutical companies are investing in research aimed at reducing attack frequency and improving disease control. Greater access to specialist care, patient education programs, and improved diagnostic testing are also supporting treatment adoption. In addition, the development of more convenient administration methods is helping address patient preferences and treatment-management requirements.

The future prospects of this market will be influenced by advances in targeted treatment, preventive therapies, and improved approaches to identifying patients at risk of recurrent episodes. Research into novel biological pathways may create opportunities for therapies with improved effectiveness and dosing convenience. Better diagnostic awareness could also reduce delays in identifying hereditary and medication-related forms of angioedema. However, treatment affordability, differences in healthcare access, and the need for rapid intervention during severe episodes remain important considerations. Continued clinical research, patient education, and improvements in emergency preparedness are expected to support further development of the treatment landscape.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Condition Type

• Allergic Angioedema
• Drug-Induced Angioedema
• Idiopathic Angioedema
• Hereditary Angioedema (HAE)

By Drug Type

• C1 Esterase Inhibitor
• Selective Bradykinin B2 Receptor Antagonist
• Kallikrein Inhibitor
• Others

By Route of Administration

• Injection
• Oral

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Takeda, CSL, BioCryst Pharmaceuticals, Pharming Group, KalVista Pharmaceuticals, Ionis Pharmaceuticals, Pharvaris, Intellia Therapeutics, Astria Therapeutics, Adverum Biotechnologies, Arrowhead Pharmaceuticals, Sanofi, Attune Pharmaceuticals, ADARx Pharmaceuticals, Regeneron Pharmaceuticals, Otsuka Pharmaceutical, Grifols, Sobi, Octapharma, Kedrion Biopharma

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANGIOEDEMA TREATMENT MARKET: BY CONDITION TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Condition Type
• 4.2. Allergic Angioedema Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Drug-Induced Angioedema Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Idiopathic Angioedema Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Hereditary Angioedema (HAE) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANGIOEDEMA TREATMENT MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Type
• 5.2. C1 Esterase Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Selective Bradykinin B2 Receptor Antagonist Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Kallikrein Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANGIOEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANGIOEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANGIOEDEMA TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Condition Type
  • 8.2.2 By Drug Type
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Condition Type
  • 8.3.2 By Drug Type
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Spain
  • 8.3.10 Russia
  • 8.3.11 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Condition Type
  • 8.4.2 By Drug Type
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 China
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 India
  • 8.4.9 Australia
  • 8.4.10 South East Asia
  • 8.4.11 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Condition Type
  • 8.5.2 By Drug Type
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Condition Type
  • 8.6.2 By Drug Type
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ANGIOEDEMA TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Takeda
  • 10.2.2 CSL
  • 10.2.3 BioCryst Pharmaceuticals
  • 10.2.4 Pharming Group
  • 10.2.5 KalVista Pharmaceuticals
  • 10.2.6 Ionis Pharmaceuticals
  • 10.2.7 Pharvaris
  • 10.2.8 Intellia Therapeutics
  • 10.2.9 Astria Therapeutics
  • 10.2.10 Adverum Biotechnologies
  • 10.2.11 Arrowhead Pharmaceuticals
  • 10.2.12 Sanofi
  • 10.2.13 Attune Pharmaceuticals
  • 10.2.14 ADARx Pharmaceuticals
  • 10.2.15 Regeneron Pharmaceuticals
  • 10.2.16 Otsuka Pharmaceutical
  • 10.2.17 Grifols
  • 10.2.18 Sobi
  • 10.2.19 Octapharma
  • 10.2.20 Kedrion Biopharma